During 2019, the company faced rapid technological development, particularly with respect to computing, automation, artificial intelligence, mobile connectivity, communications, and digitization in most of its served markets. The company is making significant investments, organically and through acquisitions, to address the rapid pace of technological change in its served markets and to globalize its manufacturing, research and development, and customer-facing resources in order to be responsive to customers throughout the world and improve the efficiency of operations. The company's long-term growth and profitability will depend on its ability to expand its business in high-growth geographies and high-growth market segments, develop innovative and differentiated new products and services with higher gross profit margins, and effectively address the demands of an increasingly regulated global environment. The company’s life sciences segment offers a broad range of research tools and is a leading provider of filtration, separation, and purification technologies to various sectors, which underscores the importance of leveraging technology resources to enhance organizational capabilities. The company’s diagnostics segment provides analytical instruments, reagents, consumables, software, and services that are essential for diagnosing disease and making treatment decisions, highlighting the integration of IT capabilities in supporting business needs. The company recognizes the importance of mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities. The ongoing application of productivity improvement initiatives has contributed to improved operating profit margins and operational efficiency. The company’s strategic management practices include monitoring key competitors and customers to gauge relative performance and the outlook for the future, which is essential for maintaining competitive advantage. The company’s investments in technology management and infrastructure capability are aimed at enhancing operational flexibility and improving information management processes. The company’s acquisitions and dispositions, including the acquisition of the GE biopharma business, are expected to provide additional sales and earnings growth opportunities, thereby expanding the business's geographic and product line diversity. The company’s commitment to process optimization and business process management reflects its focus on enhancing performance metrics and achieving operational excellence. The strategic resource allocation decisions made by management are designed to support the company’s long-term objectives and enhance its market responsiveness. The company continues to evaluate its technology portfolio and investment choices to ensure alignment with organizational goals and market dynamics. The integration of digital technologies and innovation partnerships is critical for the company's ability to respond to consumer demands and capitalize on emerging market opportunities. The company’s focus on developing actionable investments and enhancing its IT effectiveness is integral to its overall business strategy and performance outcomes.